These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22448022)

  • 21. Diagnostic and management challenges for childhood tuberculosis in the era of HIV.
    Marais BJ; Graham SM; Cotton MF; Beyers N
    J Infect Dis; 2007 Aug; 196 Suppl 1():S76-85. PubMed ID: 17624829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus and tuberculosis coinfection in children: challenges in diagnosis and treatment.
    Verhagen LM; Warris A; van Soolingen D; de Groot R; Hermans PW
    Pediatr Infect Dis J; 2010 Oct; 29(10):e63-70. PubMed ID: 20651637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities.
    Churchyard GJ; Scano F; Grant AD; Chaisson RE
    J Infect Dis; 2007 Aug; 196 Suppl 1():S52-62. PubMed ID: 17624827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustainable tuberculosis drug development.
    Wallis RS
    Clin Infect Dis; 2013 Jan; 56(1):106-13. PubMed ID: 23042970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of tuberculosis: present status and future prospects.
    Onyebujoh P; Zumla A; Ribeiro I; Rustomjee R; Mwaba P; Gomes M; Grange JM
    Bull World Health Organ; 2005 Nov; 83(11):857-65. PubMed ID: 16302043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drugs for active tuberculosis.
    Ginsberg AM
    Semin Respir Crit Care Med; 2008 Oct; 29(5):552-9. PubMed ID: 18810688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The growing shadow of tuberculosis.
    Nary G
    J Int Assoc Physicians AIDS Care; 1995 Apr; 1(3):26-7. PubMed ID: 11362486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries.
    Friedland G; Abdool Karim S; Abdool Karim Q; Lalloo U; Jack C; Gandhi N; El Sadr W
    Clin Infect Dis; 2004 Jun; 38 Suppl 5():S421-8. PubMed ID: 15156433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.
    Hawken MP; Muhindi DW
    Int J Tuberc Lung Dis; 1999 Aug; 3(8):646-50. PubMed ID: 10460096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.
    Blomberg B; Spinaci S; Fourie B; Laing R
    Bull World Health Organ; 2001; 79(1):61-8. PubMed ID: 11217670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation issues in tuberculosis/HIV program collaboration and integration: 3 case studies.
    Friedland G; Harries A; Coetzee D
    J Infect Dis; 2007 Aug; 196 Suppl 1():S114-23. PubMed ID: 17624820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis.
    Dye C; Williams BG; Espinal MA; Raviglione MC
    Science; 2002 Mar; 295(5562):2042-6. PubMed ID: 11896268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment.
    Engohang-Ndong J
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1789-800. PubMed ID: 22991970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
    Kwara A; Flanigan TP; Carter EJ
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implications of the current tuberculosis treatment landscape for future regimen change.
    Wells WA; Konduri N; Chen C; Lee D; Ignatius HR; Gardiner E; Schwalbe NR
    Int J Tuberc Lung Dis; 2011 Jun; 15(6):746-53. PubMed ID: 21575293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS.
    Williams BG; Dye C
    Science; 2003 Sep; 301(5639):1535-7. PubMed ID: 12920302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Isolation of Mycobacterium tuberculosis with primary resistance to chemotherapeutic agents in patients with HIV infection].
    Sesma P; Esteban J; Gegundez MI; Manrique A; Espinosa P; Fernández-Guerrero ML
    Enferm Infecc Microbiol Clin; 1992; 10(7):416-20. PubMed ID: 1450261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.